Israel - engelsk - Ministry of Health

novartis israel ltd - mitoxantrone as hydrochloride - concentrate for solution for infusion - mitoxantrone as hydrochloride 2 mg/ml - mitoxantrone - mitoxantrone - treatment of advanced breast cancer, non-hodgkin's lymphomas, acute non lymphocytic leukemia palliation of non resectable primary hepatocellular carcinoma. mitoxantrone in combination with corticosterolds is indicated for inital chemotherapy in patients with pain due to advanced hormone-refractory prostate cancer. for reduction of neurologic disability and/or frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remmitting multiple sclerosis (patients whose neurologic status is significantly abnormal between relapses), for patients 18-55 years old.בקשה לשינוי התוויה: 5/1/2021mitoxantrone is indicated in the treatment of metastatic breast cancer.mitoxantrone is indicated in the treatment of non-hodgkin’s lymphoma.mitoxantrone is indicated for the treatment of acute myeloid leukaemia (aml) in adults.mitoxantrone in combination regimens is indicated in the remission-induction treatment of blast crisis in chronic myeloid leukaemia.mitoxantrone is indicated in combination with corticosteroids for palliation (e.g. pain relief) related to advanced castrate resistant prostate cancer.mitoxantrone is indicated for treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disability where no alternative therapeutic options exist.

Malta - engelsk - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 10 mg - antineoplastic agents

Malta - engelsk - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 20 mg - antineoplastic agents

Malta - engelsk - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 30 mg - antineoplastic agents

Malta - engelsk - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mitoxantrone - concentrate for solution for infusion - mitoxantrone 2 mg/ml - antineoplastic agents

Malta - engelsk - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mitoxantrone - concentrate for solution for infusion - mitoxantrone 2 mg/ml - antineoplastic agents

Malta - engelsk - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - mitoxantrone - concentrate for solution for infusion - mitoxantrone 2 mg/ml - antineoplastic agents

USA - engelsk - NLM (National Library of Medicine)

fresenius kabi usa, llc - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection, usp is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection, usp is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability.  mitoxantrone injection, usp in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mi

USA - engelsk - NLM (National Library of Medicine)

hospira, inc. - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mitoxantrone in combination with other approved

USA - engelsk - NLM (National Library of Medicine)

teva parenteral medicines, inc. - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection usp (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection usp (concentrate) is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. mitoxantrone injection usp (concentrate) in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced